| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Former 10% Owner | Director, 10% Owner
5 companies
Gadicke Ansbert is a Director, 10% Owner at KLRS, with reported holdings spanning 5 companies. Recent filings cover 4 purchases and 117 sales. Those positions are worth an estimated $620.8M at current prices.
Our model assigns Gadicke Ansbert a strong insider score of 85/100, based on 79 past trades. Over a 12-month horizon, 98.0% of those trades were profitable, with an average 12-month return of +56.6%.
Gadicke Ansbert's largest disclosed position is in CGEM as Director, 10% Owner, worth about $222.3M. The recent filings there lean toward selling, a net 2,396 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2021 | RPTX Repare Therapeutics Inc. | 10% Owner | Sell | 46,904 | $34.37 | $1,611,963.82 | -1.0% | -2.6% | -75.5% | |
| May 4, 2021 | HOWL Werewolf Therapeutics, Inc. | 10% Owner | Buy | 245,000 | $16.00 | $3,920,000.00 | +3.8% | +3.3% | -66.7% | |
| Mar 12, 2021 | RPTX Repare Therapeutics Inc. | 10% Owner | Sell | 695,000 | $28.18 | $19,585,100.00 | -12.9% | +19.5% | -56.9% | |
| Jan 12, 2021 | CGEM Cullinan Therapeutics, Inc. | Director, 10% Owner | Buy | 300,000 | $21.00 | $6,300,000.00 | +3.9% | - | - | |
| Jun 23, 2020 | RPTX Repare Therapeutics Inc. | 10% Owner | Buy | 500,000 | $20.00 | $10,000,000.00 | +10.2% | - | - |